W dniach od 2 kwietnia do 5 kwietnia 2024 r. prowadzone będą prace związane z wdrożeniem nowej wersji systemu Repozytorium UJ. Nie będzie możliwe wprowadzanie nowych informacji do repozytorium. Za utrudnienia przepraszamy.
Finansowanie najdroższych terapii lekowych w Polsce a problemy w dostępie do nich : analiza poziomu finansowania i opłacalności programów terapeutycznych
Finansowanie najdroższych terapii lekowych w Polsce a problemy w dostępie do nich : analiza poziomu finansowania i opłacalności programów terapeutycznych
Finansowanie najdroższych terapii lekowych w Polsce a problemy w dostępie do nich : analiza poziomu finansowania i opłacalności programów terapeutycznych
wariant tytułu:
Financing of the most expensive drug therapies in Poland : analysis of the funding level of the therapeutic health programs
autor:
Seweryn Michał , Koperny Magdalena, Drobisz-Miętkiewicz Angelika
tytuł czasopisma:
Zeszyty Naukowe Ochrony Zdrowia, Zdrowie Publiczne i Zarządzanie
One of the most discussed topics about organization of the Polish
health care system is providing full accessibility to the financing of
the latest drug therapies. According to the institutions implementing
the programs most serious causes of problems in access to innovative
pharmacotherapy are too low level of funding programs and their low
profitability, or even hospitals pay the extra to such benefits.
Due to the increasingly high cost of treatment of severe illnesses and ongoing
development of new medical technologies, in choosing the method
of treatment are taken into account the results of economic analyzes.
The authors, by analyzing the level of funding and implementation of
treatment programs, have attempted to answer the question whether the
claims are true, and health care providers and Polish patients have equal
access to the most expensive drug therapies? To verify the above hypothesis
also performed an cost analysis of selected therapeutic programs.
Cost analysis conducted based on the identification and analysis of the
costs of four therapeutic health programs indicated that the refund value
of National Health Fund for providers implementing health programs
may be substantially higher than the costs incurred by them.
The current way of financing most expensive innovation therapy has many weaknesses, but most frequently mentioned causes of the problems with
the availability of treatment programs are not supported by actual data.